CR9832A - Compuestos de pirimidina amida como inhibidores de pgds - Google Patents

Compuestos de pirimidina amida como inhibidores de pgds

Info

Publication number
CR9832A
CR9832A CR9832A CR9832A CR9832A CR 9832 A CR9832 A CR 9832A CR 9832 A CR9832 A CR 9832A CR 9832 A CR9832 A CR 9832A CR 9832 A CR9832 A CR 9832A
Authority
CR
Costa Rica
Prior art keywords
amida
pyrimidine compounds
compound
pgds inhibitors
pgds
Prior art date
Application number
CR9832A
Other languages
English (en)
Inventor
Suzanne C Aldous
John Ziqi Jiang
Jinqi Lu
Liang Ma
Lan Mu
Harry Randall Munson
Jeffrey Stephen Sabol
Sukanthini Thurairatnam
Christopher Loren Vandeusen
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of CR9832A publication Critical patent/CR9832A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se refiere a un compuesto de formula (I) en la que R1, R2, R3 y L1 son como se han definido anteriormente, una composicion farmaceutica que comprende el compuesto, y el uso del compuesto para tratar trastornos alergicos y/o inflamatorios, particularmente trastornos tales como rinitis alergica, asma y/o enfermedad pulmonar obstructiva cronica (COPD).
CR9832A 2005-10-04 2008-03-26 Compuestos de pirimidina amida como inhibidores de pgds CR9832A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72357005P 2005-10-04 2005-10-04

Publications (1)

Publication Number Publication Date
CR9832A true CR9832A (es) 2008-06-18

Family

ID=37635758

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9832A CR9832A (es) 2005-10-04 2008-03-26 Compuestos de pirimidina amida como inhibidores de pgds

Country Status (27)

Country Link
US (1) US8202863B2 (es)
EP (1) EP1937652B1 (es)
JP (1) JP5452925B2 (es)
KR (1) KR101457966B1 (es)
CN (2) CN101538246B (es)
AR (1) AR056871A1 (es)
AU (1) AU2006299428B2 (es)
BR (1) BRPI0616815A2 (es)
CA (1) CA2624749C (es)
CR (1) CR9832A (es)
DO (1) DOP2006000210A (es)
EC (1) ECSP088335A (es)
ES (1) ES2514471T3 (es)
IL (1) IL190411A (es)
MA (1) MA29925B1 (es)
MY (1) MY151172A (es)
NO (1) NO20082000L (es)
NZ (1) NZ567208A (es)
PE (2) PE20070589A1 (es)
RU (1) RU2420519C2 (es)
SG (1) SG166121A1 (es)
TN (1) TNSN08104A1 (es)
TW (1) TWI415839B (es)
UA (1) UA93213C2 (es)
UY (1) UY29840A1 (es)
WO (1) WO2007041634A1 (es)
ZA (1) ZA200802222B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759350B2 (en) * 2005-09-15 2010-07-20 Orchid Research Laboratories Ltd. Pyrimidine carboxamides
DOP2006000210A (es) 2005-10-04 2007-06-15 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
EP2004596A2 (en) 2006-04-11 2008-12-24 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
CA2672373C (en) 2006-12-19 2011-08-30 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
EP2132196A1 (en) 2007-02-26 2009-12-16 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
KR101669432B1 (ko) 2007-08-27 2016-10-26 다트 뉴로사이언스 (케이만) 엘티디. 치료적 이속사졸 화합물
AU2008310660A1 (en) * 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
KR20100075631A (ko) 2007-10-11 2010-07-02 버텍스 파마슈티칼스 인코포레이티드 전압­개폐 나트륨 채널의 억제제로서 유용한 아릴 아미드
WO2009049181A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Amides useful as inhibitors of voltage-gated sodium channels
WO2009064449A1 (en) * 2007-11-13 2009-05-22 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
EP2261210B1 (en) * 2008-02-06 2014-10-22 Msd K.K. 3-substituted sulfonyl piperazine derivative
WO2009140364A2 (en) * 2008-05-13 2009-11-19 Cayman Chemical Company Methods for assaying compounds or agents for ability to displace potent ligands of hematopoietic prostaglandin d synthase
CA2725481A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
TW201010997A (en) 2008-06-18 2010-03-16 Pfizer Ltd Nicotinamide derivatives
US8536185B2 (en) 2008-09-22 2013-09-17 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
WO2010056044A2 (ko) * 2008-11-11 2010-05-20 (주)아모레퍼시픽 바닐로이드 수용체 길항제로 작용하는 신규 화합물, 이의 이성질체 또는 이의 약제학적으로 허용 가능한 염 및 이를 포함하는 약학 조성물
KR101367057B1 (ko) 2009-03-17 2014-02-25 (주)아모레퍼시픽 피부 자극 완화용 조성물
KR101252335B1 (ko) 2009-07-16 2013-04-08 (주)아모레퍼시픽 피부 노화 방지용 조성물
ES2564454T3 (es) 2009-03-09 2016-03-22 Taiho Pharmaceutical Co., Ltd. Compuesto de piperazina que puede inhibir la prostaglandina D sintasa
NZ599099A (en) * 2009-10-08 2013-05-31 Sanofi Sa Phenyloxadiazole derivatives as pgds inhibitors
WO2011090062A1 (ja) 2010-01-22 2011-07-28 大鵬薬品工業株式会社 Pgds阻害作用を有するピペラジン化合物
US9320723B2 (en) * 2010-05-03 2016-04-26 University Of Rochester Methods of treating thyroid eye disease
AU2011261164A1 (en) * 2010-06-01 2012-12-13 The University Of Queensland Haematopoietic-prostaglandin D2 synthase inhibitors
WO2012033069A1 (ja) 2010-09-07 2012-03-15 大鵬薬品工業株式会社 プロスタグランジンd合成酵素を阻害するピペリジン化合物
KR101271223B1 (ko) 2011-01-27 2013-06-07 한국과학기술연구원 아미노피리미딘 유도체 및 이를 포함하는 세포외 신호조절 키나제의 제해제
CN104159587A (zh) * 2012-01-06 2014-11-19 南佛罗里达大学 组合物、使用方法、以及治疗方法
CN104926808B (zh) * 2012-08-24 2018-09-14 广东东阳光药业有限公司 二氢嘧啶类化合物及其在药物中的应用
CN108430992A (zh) 2015-12-17 2018-08-21 阿斯特克斯医疗公司 作为h-pgds抑制剂的喹啉-3-甲酰胺
WO2017160832A1 (en) * 2016-03-14 2017-09-21 Emory University Amide-sulfamide derivatives, compositions, and uses related to cxcr4 inhibition
JOP20190072A1 (ar) 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
TW201908311A (zh) 2017-06-13 2019-03-01 英商葛蘭素史克智慧財產發展有限公司 化合物
WO2019084529A1 (en) * 2017-10-29 2019-05-02 China Medical University ADAM9 INHIBITORS AND USES THEREOF
JP2021506811A (ja) 2017-12-13 2021-02-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｈ−ｐｇｄｓの阻害剤として作用する縮合ピリジン
MX2020009887A (es) * 2018-03-23 2020-10-12 Step Pharma S A S Derivados de aminopiridina como inhibidores de ctps1.
CN112969698A (zh) 2018-11-08 2021-06-15 葛兰素史密斯克莱知识产权发展有限公司 化学化合物
BR112022023025A2 (pt) * 2020-05-13 2023-03-28 Chdi Foundation Inc Moduladores de htt para tratar doença de huntington
CN115667259B (zh) 2020-06-19 2025-06-17 佐藤制药株式会社 抑制h-pgds的稠环化合物
US12331046B2 (en) * 2020-10-23 2025-06-17 Nimbus Clotho, Inc. CTPS1 inhibitors and uses thereof
CN113004208A (zh) * 2021-03-08 2021-06-22 沈阳药科大学 一种抑制黄嘌呤氧化酶活性的化合物及制备方法和应用
US12281116B2 (en) 2021-11-17 2025-04-22 Chdi Foundation, Inc. HTT modulators for treating Huntington's disease
WO2023113023A1 (ja) 2021-12-17 2023-06-22 佐藤製薬株式会社 Ｈ－ｐｇｄｓを阻害するアザインドール誘導体
CA3245288A1 (en) * 2022-02-28 2025-06-13 Shionogi & Co., Ltd. INDAZOLE COMPOUND AND ITS PHARMACEUTICAL USE

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2934543A1 (de) * 1979-08-27 1981-04-02 Basf Ag, 6700 Ludwigshafen Substituierte n-benzoylanthranilsaeurederivate und deren anydroverbindungen, verfahren zu ihrer herstellung und ihre verwendung als herbizide
JPH03112985A (ja) * 1989-09-28 1991-05-14 Morishita Pharmaceut Co Ltd Ｎ―（１ｈ―テトラゾール―５―イル）―２―フェニル―５―ピリミジンカルボキシアミド類及びその合成用中間体
GB9405347D0 (en) * 1994-03-18 1994-05-04 Agrevo Uk Ltd Fungicides
JP2000226372A (ja) * 1999-02-01 2000-08-15 Nippon Soda Co Ltd アミド化合物、その製造方法及び農園芸用殺虫剤
JP2002003370A (ja) * 1999-09-20 2002-01-09 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
EP1218336A2 (en) * 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
MY138097A (en) * 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
JP2003112985A (ja) 2001-10-01 2003-04-18 Nre Happiness Kk 食品残渣肥、飼料原料化システムおよびそれに使用する破砕貯留処理ユニット並びに乾燥冷却処理ユニット
JPWO2004011430A1 (ja) * 2002-07-25 2005-11-24 アステラス製薬株式会社 ナトリウムチャネル阻害剤
JP4595542B2 (ja) * 2002-07-30 2010-12-08 萬有製薬株式会社 ベンズイミダゾール誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤
EP1606289B1 (en) * 2003-02-14 2009-12-02 Glaxo Group Limited Carboxamide derivatives
PT1471057E (pt) * 2003-04-25 2006-05-31 Actimis Pharmaceuticals Inc Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2
MXPA06003949A (es) * 2003-10-07 2006-06-27 Renovis Inc Compuestos amida como ligandos del canal de ion y su uso.
CA2553968A1 (en) * 2004-01-23 2005-08-11 Amgen Inc. Vanilloid receptor ligands and their use in treatments of inflammatory and neuropathic pain
DOP2006000210A (es) 2005-10-04 2007-06-15 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds

Also Published As

Publication number Publication date
EP1937652A1 (en) 2008-07-02
RU2420519C2 (ru) 2011-06-10
ECSP088335A (es) 2008-05-30
AU2006299428B2 (en) 2012-04-26
IL190411A0 (en) 2008-11-03
AU2006299428A1 (en) 2007-04-12
SG166121A1 (en) 2010-11-29
JP2009510170A (ja) 2009-03-12
KR101457966B1 (ko) 2014-11-04
MY151172A (en) 2014-04-30
CN101538246A (zh) 2009-09-23
IL190411A (en) 2013-09-30
CA2624749A1 (en) 2007-04-12
ES2514471T3 (es) 2014-10-28
CN101282943A (zh) 2008-10-08
TWI415839B (zh) 2013-11-21
US8202863B2 (en) 2012-06-19
BRPI0616815A2 (pt) 2011-07-05
DOP2006000210A (es) 2007-06-15
WO2007041634A1 (en) 2007-04-12
EP1937652B1 (en) 2014-07-30
TW200812977A (en) 2008-03-16
UY29840A1 (es) 2007-05-31
RU2008117170A (ru) 2009-11-10
PE20110118A1 (es) 2011-03-08
KR20080050611A (ko) 2008-06-09
ZA200802222B (en) 2009-09-30
UA93213C2 (en) 2011-01-25
JP5452925B2 (ja) 2014-03-26
NZ567208A (en) 2011-03-31
US20080227782A1 (en) 2008-09-18
PE20070589A1 (es) 2007-06-22
NO20082000L (no) 2008-06-09
MA29925B1 (fr) 2008-11-03
CA2624749C (en) 2011-08-16
CN101538246B (zh) 2014-07-16
TNSN08104A1 (en) 2009-07-14
AR056871A1 (es) 2007-10-31

Similar Documents

Publication Publication Date Title
CR9832A (es) Compuestos de pirimidina amida como inhibidores de pgds
SV2009002861A (es) Compuestos de pirimidina amida como inhibidores de pgds
PA8774101A1 (es) Compuesto de pirmidina
CL2011002787A1 (es) Compuestos derivados de 1-cianoetilheterociclilcarboxamida sustituidos, inhibidores de dipeptidilpeptidasa i (dppi) o catepsina c; composicion farmaceutica; combinacion faramceutica; y su uso en el tratamiento del asma, la enfermedad obstructiva cronica o la rinitis alergica.
ECSP14013173A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida
CO2019008986A2 (es) Derivados de tirosinamida como inhibidores de rho-quinasa
ECSP11010948A (es) Inhibidores de las enzimas de proteína cinasa activadas por
GT200900289A (es) Compuestos organicos.-
CL2009000198A1 (es) Compuestos derivados del acido {2'-[(amino n,n-disustituido)-metil]-bifenil-3-il} acetico, mediadores de prostaglandina d2; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad respiratoria, alergica o inflamatoria, tal como el asma, epoc o rinitis alergica.
CO6321265A2 (es) Compuestos de 2-amido-3-metil pirrolo pirimidinona fenilo -sustituidos como inhibidores bace-1 composiciones y su uso
PE20131464A1 (es) Derivados de quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinasa
CL2014000813A1 (es) El compuesto 1-pirazolil-3-(4-((2-anilinopirimidin-4-il)oxi)naftalen-1-il)urea o sus sales, inhibidor de proteinas cinasas actividas por mitogeno p38; forma sólida cristalina; composicion farmaceutica; combinacion farmaceutica; y su uso en asma, fibrosis quistica, rinitis alergica, psoriasis, entre otras
NI201100081A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa - iv para el tratamiento o prevención de diabetes.
PA8511301A1 (es) Carboxiamidas de pirimidina utiles como inhibidores de isozimas pde4
CL2010001348A1 (es) Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad.
CL2007001283A1 (es) Compuestos derivados de pirazinona
CL2009000915A1 (es) Compuestos derivados de 1-ciano-3-pirrolidinil-bencenosulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica (copd).
CL2011002463A1 (es) Compuestos heterociclicos, agonistas del receptor de glucocorticoide; composicion farmaceutica que comprende a dicho compuesto; composicion farmaceutica; kit farmaceutico; uso del compuesto para tratar el asma, enfermedad pulmonar obstructiva cronica o rinitis alergica.
CL2007001481A1 (es) Compuestos derivados de pirrolidina sustituidas, inhibidores de proteasa activadora de canal; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como fibrosis quistica, bronquitis cronica, epoc, asma e infecciones de las vias r
CL2011002461A1 (es) Compuestos derivados de tipo amida de compuestos [3,2-c] pirazol con actividad glucocorticoide utiles en condiciones inflamatorias y alergicas como asma, epoc o rinitis alergica.
AR078552A1 (es) Derivados de feniloxadiazol como agentes inhibidores de las pgds
UY29506A1 (es) Nuevas formas cristalinas de bromuro de tiotropio
CU20100111A7 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares
ECSP088287A (es) Una combinación de compuestos que puede ser utilizada en el tratamiento de enfermedades respiratorias, especialmente enfermedad pulmonar obstructiva crónica (epoc) y asma
CL2008003495A1 (es) Compuestos derivados de pirazol; composicion farmaceutica, metodo de preparacion y; su uso para tratar una enfermedad mediada por 5-lo tal como asma, broncocontriccion, enfisema, enfermedades obstructivas o inflamatorias de las vias respiratorias, bronquitis, lesion pulmonar aguda, bronquiectasia, rinitis alergica, entre otras.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)